CEFTOLOZANE\TAZOBACTAM: 1,098 Adverse Event Reports & Safety Profile
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
1,098
Total FAERS Reports
259 (23.6%)
Deaths Reported
327
Hospitalizations
1,098
As Primary/Secondary Suspect
59
Life-Threatening
22
Disabilities
Active Ingredient: CEFTOLOZANE SULFATE\TAZOBACTAM SODIUM ·
First Report: 2015 · Latest Report: 20250724
What Are the Most Common CEFTOLOZANE\TAZOBACTAM Side Effects?
#1 Most Reported
Off label use
180 reports (16.4%)
#2 Most Reported
Product use in unapproved indication
156 reports (14.2%)
#3 Most Reported
Death
99 reports (9.0%)
All CEFTOLOZANE\TAZOBACTAM Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Off label use | 180 | 16.4% | 28 | 42 |
| Product use in unapproved indication | 156 | 14.2% | 30 | 33 |
| Death | 99 | 9.0% | 99 | 11 |
| Drug ineffective | 94 | 8.6% | 47 | 42 |
| No adverse event | 89 | 8.1% | 0 | 1 |
| Pathogen resistance | 74 | 6.7% | 13 | 15 |
| Product use issue | 71 | 6.5% | 9 | 12 |
| Drug resistance | 53 | 4.8% | 14 | 24 |
| Pseudomonas infection | 36 | 3.3% | 13 | 22 |
| Multiple organ dysfunction syndrome | 34 | 3.1% | 34 | 14 |
| Septic shock | 31 | 2.8% | 22 | 25 |
| Overdose | 30 | 2.7% | 4 | 11 |
| Agranulocytosis | 29 | 2.6% | 0 | 28 |
| Pneumonia | 29 | 2.6% | 19 | 9 |
| Pancytopenia | 27 | 2.5% | 1 | 25 |
| Sepsis | 27 | 2.5% | 23 | 5 |
| Condition aggravated | 26 | 2.4% | 14 | 13 |
| Thrombocytopenia | 26 | 2.4% | 2 | 12 |
| Acute kidney injury | 25 | 2.3% | 2 | 18 |
| Incorrect dose administered | 25 | 2.3% | 5 | 3 |
Who Reports CEFTOLOZANE\TAZOBACTAM Side Effects? Age & Gender Data
Gender: 38.2% female, 61.8% male. Average age: 55.9 years. Most reports from: US. View detailed demographics →
Is CEFTOLOZANE\TAZOBACTAM Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2015 | 21 | 4 | 4 |
| 2016 | 39 | 10 | 16 |
| 2017 | 93 | 36 | 43 |
| 2018 | 72 | 16 | 34 |
| 2019 | 73 | 11 | 38 |
| 2020 | 84 | 29 | 33 |
| 2021 | 6 | 1 | 3 |
| 2022 | 40 | 19 | 7 |
| 2023 | 49 | 21 | 12 |
| 2024 | 39 | 7 | 12 |
| 2025 | 16 | 0 | 4 |
What Is CEFTOLOZANE\TAZOBACTAM Used For?
| Indication | Reports |
|---|---|
| Pseudomonas infection | 205 |
| Pneumonia | 139 |
| Pneumonia pseudomonal | 101 |
| Sepsis | 50 |
| Product used for unknown indication | 33 |
| Osteomyelitis bacterial | 32 |
| Infection | 29 |
| Abdominal infection | 28 |
| Cellulitis | 27 |
| Osteomyelitis | 26 |
CEFTOLOZANE\TAZOBACTAM vs Alternatives: Which Is Safer?
CEFTOLOZANE\TAZOBACTAM vs CEFTRIAXONE
CEFTOLOZANE\TAZOBACTAM vs CEFTRIAXONE\CEFTRIAXONE
CEFTOLOZANE\TAZOBACTAM vs CEFUROXIME
CEFTOLOZANE\TAZOBACTAM vs CEFUROXIME AXETIL
CEFTOLOZANE\TAZOBACTAM vs CELEBREX
CEFTOLOZANE\TAZOBACTAM vs CELECOXIB
CEFTOLOZANE\TAZOBACTAM vs CELIPROLOL
CEFTOLOZANE\TAZOBACTAM vs CELLCEPT
CEFTOLOZANE\TAZOBACTAM vs CEMIPLIMAB
CEFTOLOZANE\TAZOBACTAM vs CEMIPLIMAB-RWLC
Official FDA Label for CEFTOLOZANE\TAZOBACTAM
Official prescribing information from the FDA-approved drug label.